Terms: = Leukemia AND SYK, P43405, 6850, ENSG00000165025 AND Treatment
126 results:
1. [Research Progress of Targeted Therapy for Chronic Lymphocytic leukemia/Small Lymphocytic Lymphoma --Review].
Chen D; Wang MY; Tian C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):643-646. PubMed ID: 38660880
[TBL] [Abstract] [Full Text] [Related]
2. A Non-Canonical Role for the Glycosyltransferase Enzyme UGT2B17 as a Novel Constituent of the B Cell Receptor Signalosome.
Wagner A; Rouleau M; Villeneuve L; Le T; Peltier C; Allain ÉP; Beaudoin C; Tremblay S; Courtier F; Nguyen Van Long F; Laverdière I; Lévesque É; Banerji V; Vanura K; Guillemette C
Cells; 2023 May; 12(9):. PubMed ID: 37174695
[TBL] [Abstract] [Full Text] [Related]
3. Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (
Chin L; Wong CYG; Gill H
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834572
[TBL] [Abstract] [Full Text] [Related]
4. Heterogeneity of Patient-Derived Acute Myeloid leukemia Cells Subjected to syk In Vitro Inhibition.
Brattås MK; Hemsing AL; Rye KP; Hatfield KJ; Reikvam H
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499034
[TBL] [Abstract] [Full Text] [Related]
5. Recent advances in understanding spleen tyrosine kinase (syk) in human biology and disease, with a focus on fostamatinib.
Cooper N; Ghanima W; Hill QA; Nicolson PL; Markovtsov V; Kessler C
Platelets; 2023 Dec; 34(1):2131751. PubMed ID: 36331249
[TBL] [Abstract] [Full Text] [Related]
6. Population Pharmacokinetics of Mivavotinib (TAK-659), a Dual Spleen Tyrosine Kinase and FMS-Like Tyrosine Kinase 3 Inhibitor, in Patients With Advanced Solid Tumors or Hematologic Malignancies.
Li C; Watson K; Wang S; Diderichsen PM; Gupta N
J Clin Pharmacol; 2023 Mar; 63(3):326-337. PubMed ID: 36309821
[TBL] [Abstract] [Full Text] [Related]
7. A phase Ib trial of mivavotinib (TAK-659), a dual syk/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.
Pratz KW; Kaplan J; Levy M; Bixby D; Burke PW; Erba H; Wise-Draper TM; Roboz GJ; Papadantonakis N; Rajkhowa T; Hernandez D; Dobler I; Gregory RC; Li C; Wang S; Stumpo K; Kannan K; Miao H; Levis M
Haematologica; 2023 Mar; 108(3):705-716. PubMed ID: 36226495
[TBL] [Abstract] [Full Text] [Related]
8. Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid leukemia through Suppression of Stemness.
Liu ACH; Cathelin S; Yang Y; Dai DL; Ayyathan DM; Hosseini M; Minden MD; Tierens A; Chan SM
Cancer Res; 2022 Dec; 82(23):4325-4339. PubMed ID: 36150062
[TBL] [Abstract] [Full Text] [Related]
9. Modeling the B-cell receptor signaling on single cell level reveals a stable network circuit topology between nonmalignant B cells and chronic lymphocytic leukemia cells and between untreated cells and cells treated with kinase inhibitors.
Wolf C; Maus C; Persicke MRO; Filarsky K; Tausch E; Schneider C; Döhner H; Stilgenbauer S; Lichter P; Höfer T; Mertens D
Int J Cancer; 2022 Sep; 151(5):783-796. PubMed ID: 35527719
[TBL] [Abstract] [Full Text] [Related]
10. Kinase Inhibition as treatment for Acute and Chronic Graft-
Braun LM; Zeiser R
Front Immunol; 2021; 12():760199. PubMed ID: 34868001
[TBL] [Abstract] [Full Text] [Related]
11. Kinase Inhibitors and Interferons as Other Myeloid Differentiation Inducers in leukemia Therapy.
Takahashi S
Acta Haematol; 2022; 145(2):113-121. PubMed ID: 34673646
[TBL] [Abstract] [Full Text] [Related]
12. GPX1-associated prognostic signature predicts poor survival in patients with acute myeloid leukemia and involves in immunosuppression.
Zhang J; Peng Y; He Y; Xiao Y; Wang Q; Zhao Y; Zhang T; Wu C; Xie Y; Zhou J; Yu W; Lu D; Bai H; Chen T; Guo P; Zhang Q
Biochim Biophys Acta Mol Basis Dis; 2022 Jan; 1868(1):166268. PubMed ID: 34536536
[TBL] [Abstract] [Full Text] [Related]
13. Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype.
Elias EE; Sarapura Martinez VJ; Amondarain M; Colado A; Cordini G; Bezares RF; Fernandez Grecco H; Custidiano MDR; Sánchez Ávalos JC; Garate G; Pavlovsky MA; Borge M; Giordano M; Gamberale R
Cancer Immunol Immunother; 2022 Apr; 71(4):979-987. PubMed ID: 34467417
[TBL] [Abstract] [Full Text] [Related]
14. The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance.
Narayanan S; Wu ZX; Wang JQ; Ma H; Acharekar N; Koya J; Yoganathan S; Fang S; Chen ZS; Pan Y
Int J Biol Sci; 2021; 17(10):2652-2665. PubMed ID: 34326700
[TBL] [Abstract] [Full Text] [Related]
15. Proapoptotic and immunomodulatory effects of syk inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia.
Lam V; Best S; Kittai A; Orand K; Spurgeon SE; Liu T; Danilov AV
Br J Clin Pharmacol; 2022 Feb; 88(2):836-841. PubMed ID: 34196037
[TBL] [Abstract] [Full Text] [Related]
16. Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice.
Thomas KR; Allenspach EJ; Camp ND; Wray-Dutra MN; Khim S; Zielinska-Kwiatkowska A; Timms AE; Loftus JP; Liggitt HD; Georgopoulos K; Tasian SK; James RG; Rawlings DJ
Leukemia; 2022 Jan; 36(1):42-57. PubMed ID: 34193976
[TBL] [Abstract] [Full Text] [Related]
17. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
Smith CIE; Burger JA
Front Immunol; 2021; 12():689472. PubMed ID: 34177947
[TBL] [Abstract] [Full Text] [Related]
18. A novel somatic PLCG2 variant associated with resistance to BTK and syk inhibition in chronic lymphocytic leukemia.
Raghunathan V; Fan G; Kittai AS; Okada C; Danilov AV; Spurgeon SE
Eur J Haematol; 2021 Feb; 106(2):294-297. PubMed ID: 33089525
[TBL] [Abstract] [Full Text] [Related]
19. [High Expression Level of SP1, CSF1R, and PAK1 Correlates with Sensitivity of leukemia Cells to the Antibiotic Mithramycin].
Vagapova ER; Lebedev TD; Tikhonova AD; Goikhman BV; Ivanenko KA; Spirin PV; Prassolov VS
Mol Biol (Mosk); 2020; 54(3):522-528. PubMed ID: 32492016
[TBL] [Abstract] [Full Text] [Related]
20. Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies.
Lukas M; Velten B; Sellner L; Tomska K; Hüellein J; Walther T; Wagner L; Muley C; Wu B; Oleś M; Dietrich S; Jethwa A; Bohnenberger H; Lu J; Huber W; Zenz T
Leukemia; 2020 Nov; 34(11):2934-2950. PubMed ID: 32404973
[TBL] [Abstract] [Full Text] [Related]
[Next]
